CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis
Open Access
- 1 February 2005
- journal article
- review article
- Published by Elsevier in Genetics in Medicine
- Vol. 7 (2), 97-104
- https://doi.org/10.1097/01.gim.0000153664.65759.cf
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Corticosteroids for acute traumatic brain injuryCochrane Database of Systematic Reviews, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- CYP2C9 exon 4 mutations and warfarin dose phenotype in AsiansBlood, 2003
- Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common diseaseNature Genetics, 2003
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- The Frequency and Effects of Cytochrome P450 (CYP) 2C9 Polymorphisms in Patients Receiving WarfarinJournal of the American College of Surgeons, 2002
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Guidelines on oral anticoagulation: third editionBritish Journal of Haematology, 1998